Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors | NYU Langone Health

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Advanced Solid Tumors
Age: Between 18 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:

1. Have a histologically- or cytologically-confirmed advanced/metastatic solid tumor of any type by pathology report and have received, or been intolerant to, or been ineligible for all treatment. 2. Have stage III or stage IV disease that is not surgically removed. 3. Demonstrate adequate organ function

You may not be eligible for this study if the following are true:

1. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. 2. Has a known active central nervous system (CNS) metastasis and/or carcinomatous meningitis. 3. Has an active autoimmune disease that has required systemic treatment in the past 2 years.